Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211302 · ClinicalTrials.gov registry record · NA
Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)
A NA study, sponsored by Louisiana State University Health Sciences Center Shreveport.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT00211302 is a NA study that was terminated before completion, run by Louisiana State University Health Sciences Center Shreveport. The registered enrollment target is 8 participants.
The verdict
NCT00211302, a NA study, was terminated before completion, sponsored by Louisiana State University Health Sciences Center Shreveport.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder both before and after a switch from risperidone to aripiprazole may reveal some of the cognitive changes that correlate with the improved response, better side effect profile, and effects on other components of the negative symptom array. Further, examination of brain functional activity using functional magnetic resonance imaging (fMRI) during a verbal learning task, as well as behavioral performance and associated electroencephalographic (EEG) data of episodic memory, working memory and intermediate term verbal memory collected with the Sustained Attention and Memory Brain Function Test (SAM-BFT), may also provide data showing the neural correlates of these changes in cognition.
Interventions
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2003-08 |
| Est. Completion | 2006-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211302
The ClinicalTrials.gov registry entry for NCT00211302 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Louisiana State University Health Sciences Center Shreveport, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aripiprazole is the first listed.
NCT00211302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211302 about?
NCT00211302 is a clinical study titled "Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)". Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder both before and after a switch from risperidone to aripiprazole may reveal some of the cognitive changes that correlate with the improved response, better side effect profile, and effects on other components o...
What is the current status of trial NCT00211302?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2003-08. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00211302?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00211302?
This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.